Suppr超能文献

确定体外研究中药代动力学参数可预测性的成功标准:基于体内观察的分析

Deciding on success criteria for predictability of pharmacokinetic parameters from in vitro studies: an analysis based on in vivo observations.

作者信息

Abduljalil Khaled, Cain Theresa, Humphries Helen, Rostami-Hodjegan Amin

机构信息

Simcyp Limited (a Certara company), Sheffield, United Kingdom (K.A., T.C., H.H., A.R-H); and Manchester Pharmacy School, University of Manchester, Manchester, United Kingdom (A.R-H)

Simcyp Limited (a Certara company), Sheffield, United Kingdom (K.A., T.C., H.H., A.R-H); and Manchester Pharmacy School, University of Manchester, Manchester, United Kingdom (A.R-H).

出版信息

Drug Metab Dispos. 2014 Sep;42(9):1478-84. doi: 10.1124/dmd.114.058099. Epub 2014 Jul 2.

Abstract

Prediction accuracy of pharmacokinetic parameters is often assessed using prediction fold error, i.e., being within 2-, 3-, or n-fold of observed values. However, published studies disagree on which fold error represents an accurate prediction. In addition, "observed data" from only one clinical study are often used as the gold standard for in vitro to in vivo extrapolation (IVIVE) studies, despite data being subject to significant interstudy variability and subjective selection from various available reports. The current study involved analysis of published systemic clearance (CL) and volume of distribution at steady state (Vss) values taken from over 200 clinical studies. These parameters were obtained for 17 different drugs after intravenous administration. Data were analyzed with emphasis on the appropriateness to use a parameter value from one particular clinical study to judge the performance of IVIVE and the ability of CL and Vss values obtained from one clinical study to "predict" the same values obtained in a different clinical study using the n-fold criteria for prediction accuracy. The twofold criteria method was of interest because it is widely used in IVIVE predictions. The analysis shows that in some cases the twofold criteria method is an unreasonable expectation when the observed data are obtained from studies with small sample size. A more reasonable approach would allow prediction criteria to include clinical study information such as sample size and the variance of the parameter of interest. A method is proposed that allows the "success" criteria to be linked to the measure of variation in the observed value.

摘要

药代动力学参数的预测准确性通常使用预测倍数误差来评估,即处于观察值的2倍、3倍或n倍范围内。然而,已发表的研究对于哪种倍数误差代表准确预测存在分歧。此外,尽管数据存在显著的研究间变异性且是从各种可用报告中主观选择的,但仅来自一项临床研究的“观察数据”通常被用作体外到体内外推(IVIVE)研究的金标准。当前的研究涉及对从200多项临床研究中获取的已发表的全身清除率(CL)和稳态分布容积(Vss)值进行分析。这些参数是在静脉给药后针对17种不同药物获得的。分析数据时重点关注使用来自一项特定临床研究的参数值来判断IVIVE性能的适用性,以及从一项临床研究中获得的CL和Vss值使用预测准确性的n倍标准“预测”在另一项临床研究中获得的相同值的能力。双重标准方法受到关注,因为它在IVIVE预测中被广泛使用。分析表明,在某些情况下,当观察数据来自小样本量研究时,双重标准方法是不合理的期望。一种更合理的方法是允许预测标准纳入临床研究信息,如样本量和感兴趣参数的方差。提出了一种方法,使“成功”标准与观察值的变异度量相关联。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验